Study #2023-0527
Phase I/II open label study of Belumosudil Mesylate alone, and in combination with Dexamethasone, in patients with relapsed/refractory multiple myeloma
MD Anderson Study Status
Enrolling
Treatment Agent
Belumosudil mesylate
Description
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Multiple Myeloma
Study phase:
Physician name:
Robert Orlowski
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.